A
Aurealis Pharma AG
A game changer for chronic wounds, cancer, inflammatory diseases and beyond
About Aurealis Pharma AG
Aurealis Therapeutics is a pioneering biopharmaceutical company focused on developing advanced therapies for chronic wounds, cancer, and inflammatory diseases. Operating in the healthcare and biotechnology sectors, Aurealis Therapeutics serves patients, healthcare providers, and medical institutions. The company's business model revolves around research and development of novel treatments, leveraging cutting-edge technology to address unmet medical needs. Revenue is generated through partnerships, licensing agreements, and sales of proprietary therapies. Headquartered in Basel, Switzerland, with additional facilities in Kuopio, Finland, Aurealis Therapeutics is strategically positioned to collaborate with global healthcare leaders.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Kuopio, Finland
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Tesi
Aurealis Therapeutics
Lynx Financial
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aurealis Pharma AG on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aurealis Pharma AG on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.